Menu Search
Equities

Dr Reddy's Laboratories Ltd

RDY:NYQ

Dr Reddy's Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.99
  • Today's Change-0.31 / -2.17%
  • Shares traded1.59m
  • 1 Year change+2.46%
  • Beta0.5439
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Dr Reddy's Laboratories Ltd (ADR) have a median target of 17.01, with a high estimate of 18.31 and a low estimate of 14.76. The median estimate represents a 21.56% increase from the last price of 13.99.
High30.9%18.31
Med21.6%17.01
Low5.5%14.76

Dividends in INR

In 2024, Dr Reddy's Laboratories Ltd reported a dividend of 8.05 INR, which represents a 29.38% increase over last year. The 20 analysts covering the company expect dividends of 8.38 INR for the upcoming fiscal year, an increase of 4.16%.
Div growth (TTM)29.38%
More ▼

Earnings history & estimates in INR

On Nov 05, 2024, Dr Reddy's Laboratories Ltd (ADR) reported 2nd quarter 2025 earnings of 15.05 per share.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate-3.89%
Dr Reddy's Laboratories Ltd (ADR) reported annual 2024 earnings of 66.92 per share on May 07, 2024.
Average growth rate+22.63%
More ▼

Revenue history & estimates in INR

Dr Reddy's Laboratories Ltd (ADR) had 2nd quarter 2025 revenues of 80.38bn. This bettered the 76.50bn consensus of the 17 analysts covering the company. This was 18.95% above the prior year's 2nd quarter results.
Average growth rate+3.94%
Dr Reddy's Laboratories Ltd (ADR) had revenues for the full year 2024 of 280.11bn. This was 13.92% above the prior year's results.
Average growth rate+12.59%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.